News
-
-
PRESS RELEASE
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health, Inc. provides promising results on crofelemer for pediatric intestinal failure patients at ESPGHAN Meeting. Liquid oral crofelemer shows significant reductions in parenteral support requirements normalized to body weight -
-
PRESS RELEASE
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Jaguar Health, Inc. continues global development program for crofelemer in pediatric intestinal failure patients with MVID and SBS-IF. Special Stock Dividend and conversion of Preferred Stock announced to benefit stockholders -
-
PRESS RELEASE
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar submits NADA for Canalevia-CA1 to FDA for CID in dogs, reporting positive results in study. Crofelemer effectively treats chemotherapy-induced diarrhea -
-
PRESS RELEASE
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Jaguar Health, Inc. to explore strategic alternatives maximizing stockholder value. Updates on crofelemer program for rare intestinal failure diseases by CEO Lisa Conte at Life Sciences Virtual Investor Forum on June 24, 2026 -
-
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Magdalena's drug candidate, a coca leaf extract, shows promise for post-GLP-1 weight loss management. Preclinical study results suggest potential as weight maintenance therapy
